Spots Global Cancer Trial Database for ezh2 gof
Every month we try and update this database with for ezh2 gof cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation | NCT06068881 | Follicular Lymp... Refractory Foll... | Tazverik (Tazem... | 18 Years - | Ipsen | |
A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation | NCT06068881 | Follicular Lymp... Refractory Foll... | Tazverik (Tazem... | 18 Years - | Ipsen | |
A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation | NCT06068881 | Follicular Lymp... Refractory Foll... | Tazverik (Tazem... | 18 Years - | Ipsen | |
A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation | NCT06068881 | Follicular Lymp... Refractory Foll... | Tazverik (Tazem... | 18 Years - | Ipsen |